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Biomarkers and in vitro strategies for nephrotoxicity and renal disease assessment 
 
Abstract 
 
Acute kidney injury (AKI) is a global public health concern, impacting nearly 13.3 million patients and 
resulting in three million deaths per year. Chronic kidney disease has increased by 135% since 1990, 
representing the pathology with the fastest growth rate worldwide. The annual costs of dialysis and 
kidney transplants range between US$35,000 and US$100,000 per patient. Despite its great impact, 
kidney disease has remained mostly asymptomatic for many years. AKI continues to be a major, unmet 
medical condition for which there are no pharmacological treatments available, while animal models are 
limited to provide direction for therapeutic translation into humans. Currently, serum creatinine is the 
standard biomarker to identify nephrotoxicity; however, it is a late stage biomarker. Hence, there is a 
pressing need to study in vitro biomarkers for the assessment of nephrotoxicity in order to develop new 
and safer drugs. Understanding of the mechanisms by which molecules produce nephrotoxicity is vital in 
order to both prevent adversity and treat kidney injury. In this review, we address new technologies and 
models that may be used to identify earlier biomarkers and pathways involved in nephrotoxicity, such as 
cell culture, omics, bioinformatics platform, CRISPR/Cas9 genome-editing, in silico, organoids and 3D 
bioprinting, considering AOP. 
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1. Introduction 
 
Kidney disease is a relatively silent disease and, in most cases, only becomes apparent to those 
suffering from it in the later stages of the illness. This can be partially attributed to the fact that most 
people are not aware of the early signs associated with kidney disease, coupled with the fact that these 
signs are not always recognized by healthcare providers (MacLeod, 2009). Nonetheless, it is estimated 
that, annually, around three million deaths worldwide are caused by acute kidney injury (AKI). However, 
these numbers may be underestimated, given that half of the patients admitted to intensive care units 
develop AKI during hospitalization, and 27% of these die before being released from the hospital.  It is 
also well-known that these figures constitute only a small proportion of the total number of reported cases 
(Kellum et al., 2016). 
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AKI is an expected event that occurs relatively quickly, such as a few hours or days, after organ 
failure. The full process is still not clear. AKI is characterized by a reduction in the glomerular filtration 
rate (GFR), which leads to an increase in serum creatinine or blood urea nitrogen (BUN). However, 
measuring BUN levels is not a reliable factor to predict AKI (Kramann et al., 2015).  
The frequency of AKI has significantly increased in recent decades and is now recognized as a 
significant cause of Chronic Kidney Disease (CKD) and kidney failure in general (Levin et al., 2017). 
AKI is characterized as kidney disease that persists up to 90 days; this disease is considered chronic CKD 
when it surpasses 90 days (KDIGO, 2013; Kellum et al., 2016).  
Between 19% and 26% of the cases of AKI among hospitalized patients are caused by medication-
induced adverse effects that injure the kidney (Murugan et al., 2010). AKI is still a major, unmet medical 
problem for which no efficient pharmacological treatments exist (Mehta et al., 2015). Therefore, an 
understanding of the mechanisms by which molecules may cause harm (such as those leading to AKI) is 
vital in order to both prevent toxicity and treat kidney injury.  
Acknowledging the need for action, an increasing number of global advocacy initiatives, such as 
World Kidney Day, the International Society of Nephrology 0by25, and the Lancet Kidney Campaign 
aim to raise public awareness regarding the consequences, costs, and impact of both CKD and AKI 
(Kellum et al., 2016). 
 
2. Acute Kidney Disease 
 
Acute Kidney Injury (AKI) is a worldwide public health concern, impacting nearly 13.3 million 
patients per year (Mehta et al., 2015). AKI is associated with high morbidity and mortality - over 1.7 
million deaths per year among adults and children worldwide (Ho et al., 2014). AKI is disseminated 
throughout 72 countries and is higher in developing countries. The mortality rates of critically ill patients 
with AKI in hospitals ranges between 20% and 70% (Fortrie et al., 2019; Schmitt et al., 2008). In the 
United States alone, half a million hospital admissions each year are complicated by AKI, resulting in 
total costs of approximately $10 billion (Chertow et al., 2005). Worldwide, only half of the individuals 
who need renal replacement therapy can be treated, due to difficulties related to access to care or lack of 
diagnosis. In fact, estimates suggest that 2.5 to 5 million patients are not properly treated (Liyanage et al., 
2015).  In addition, the costs of dialysis and kidney transplants range between $35,000 and $100,000 per 
patient annually.  
Prescription drugs and other traditional low-level medication is the major cause of AKI, resulting in 
nearly 25% of all patients who use at least one nephrotoxic drug. The other 75% of the cases stem from 
other etiologies. However, the main cause of mortality and morbidity by AKI can be explained by drug-
induced nephrotoxicity in over 20% of hospital-acquired AKIs (Bellomo, 2006; Kaufman et al., 1991; 
Nash et al., 2002; Wonnacott et al., 2014). Despite this high rate, data show that only 7% of new drug 
candidates fail in preclinical trials because of nephrotoxicity (Frost and Sullivan Rang, 2007), whereas the 
incidence of patients in intensive care units developing acute kidney injury (AKI) is about 30–50% 
(Devarajan, 2005). This discrepancy may help to explain the underestimation of nephrotoxicity in 
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preclinical trials (Fuchs and Hewitt, 2011). Therefore, AKI is still a major medical condition for which no 
pharmacological treatment has been developed (Kumar et al., 2014; Lameire et al., 2013; Naughton, 
2008). 
The incidence of AKI has greatly increased over the past two decades, and it is now recognized as an 
important cause of CKD and kidney failure (Jha et al., 2013; Levin et al., 2017). However, the causal 
pathway leading to CKD is complex and will require a broad multidisciplinary response (Horton and 
Berman, 2015). Fortunately, the kidney carries an extremely regenerative potential and, in some cases, 
can be completely recovered ‘restitutio at integrum’ after an AKI. Nevertheless, there is strong evidence 
suggesting that repair can be incomplete and an episode of AKI may lead to CKD. The appearance of 
tubular response after AKI will shed light on the connection between incomplete repair and future risk of 
CKD (Kramann et al., 2015). Thus, the ‘AKI to CKD transition’ might involve incomplete renal tubule 
repair after AKI, eventually triggering interstitial renal fibrosis, making it critical to investigate the cells 
responsible for normal repair. Hence, by developing new targeted therapies to reduce injury and promote 
healing in AKI, it will be possible to determine which cells should be targeted.  
In clinical practice, the early detection of AKI has had no impact on clinical decisions. In addition, 
therapeutic possibilities for AKI are very limited, and it is unclear if there is any benefit in either early or 
late onset of renal replacement therapy. As a result, the early or late detection of AKI, in most cases, does 
not impact the clinical course of the patient. To some extent, this may explain why most biomarkers have 
not been included in the panel of classic laboratory parameters used in the clinical setting. Hence, 
advances are needed in this area in order to understand the gap related to renal disease. 
 
3. Chronic kidney disease (CKD) 
 
According to the “Kidney Disease: Improving Global Outcomes (KDIGO)” guidelines, CKD is 
characterized by abnormalities of kidney structure or function that are present for more than 3 months 
(KDIGO, 2013). 
There are few markers, such as neutrophil gelatinase-associated lipocalin (NGAL), kidney injury 
molecule1 (HAVcr-1, also named KIM-1), and nephronectin (NPNT), as well as the validated markers of 
proteinuria and microalbuminuria, that can detect the progression of AKI into CKD, which makes it an 
important area for investigation (Kashani and Kellum, 2015; Zuk and Bonventre, 2016). Among those 
who survive the long-term outcomes of AKI, patients with CKD can progress into the end-stages of renal 
disease (ESRD) or into the aggravation of pre-existing CKD, which can quickly lead to ESRD (Jha et al., 
2013; Liyanage et al., 2015; Waheed et al., 2013).  
Thus, AKI, which was previously thought to have no major consequences for recovered patients, 
may lead to poor life quality as well as long-term financial costs (Stephen C. Noble et al., 2006), which 
increases the need for public awareness regarding the early signs of the disease and investment in further 
research (Zuk and Bonventre, 2016). CKDs represent an important risk factor for cardiovascular and 
cerebrovascular diseases and progress toward ESRD (Balogun et al., 2017; Eckardt et al., 2013), which 
can only be treated by renal replacement therapies such as hemodialysis, peritoneal dialysis, or transplants 
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(Cazorla-Vázquez and Engel, 2018; Eckardt et al., 2013). Kidney failure is the most severe form of CKD 
and is fatal if not treated by dialysis or kidney transplant. Because of the uncertainty of what causes CKD, 
many patients do not receive the correct treatment (Levin et al., 2017; Pickkers et al., 2017).  
The resources required to treat CKD-associated complications (including kidney failure) impose a 
huge burden in such countries as Malaysia, Tunisia, Turkey, Chile, Mexico, and Uruguay (Muralidharan 
and White, 2015). In fact, it has been shown that the burden of CKD is on the rise, as indicated by the 
increase in both deaths and ESRD (Jha et al., 2013; Levin et al., 2017; Luyckx et al., 2018; Norton et al., 
2016; Ojo, 2014). 
Nevertheless, CKD is not on the priority list of non-communicable diseases, and only a few countries 
have explicit policies or public programs focused on preventing and controlling CKD. This unfortunate 
scenario is of concern because there is a gap between recent advances in treatment and the increase in 
mortality worldwide, thus creating barriers that limit the progress of basic research that would ultimately 
lead to new treatments (translational research type 1) (Sanchez-Niño et al., 2017). 
CKD represents the pathology with the fastest growing incidence worldwide (Kam Tao Li et al., 
2013). Its incidence has virtually duplicated between 1990 to 2010 (Lozano et al., 2012). The global 
prevalence of CKD is estimated at around 10% to 15%, with similar estimates in men and women, and is 
more frequent in high-income countries. The impaired renal function is caused by diabetes mellitus in 30–
40% of the cases, hypertension in 20%, inflammation of the glomeruli (glomerulonephritis) in 13%, 
interstitial nephritis in 10%, and polycystic kidney disease in 6%. Regardless of the cause, the common 
final outcome of almost all progressive CKDs is renal fibrosis (Humphreys, 2018; Liu, 2011).  
The actual incidence of renal disease seems to be underestimated because many deaths attributed to 
diabetes have actually been caused by renal disease (Rao et al., 2012). Moreover, hypertension and 
obesity are among the growing non-communicable diseases and represent important risk factors for CKD 
(Jha et al., 2013). Thus, identifying CKD has become imperative not only to prevent the progression of 
the disease, but also to reduce the risk of cardiovascular morbidity and mortality. Hence, new biomarkers 
are paramount for early identification of the disease. 
 
4. Biomarkers for nephrotoxicity  
 
Currently, AKI diagnosis is based on serum creatinine’s (sCr) rise and/or fall in urine production. 
These are not renal-specific markers and have major limitations.  Alternatively, there are two sets of 
biomarkers available for clinical use: neutrophil gelatinase-associated lipocalin (NGAL) and the 
combination of urinary insulin-like growth factor-binding protein 7 (IGFBP-7) and tissue inhibitor of 
metalloproteinases 2 (TIMP-2), two markers of cell-cycle arrest. These biomarkers seem to be specific 
and sensitive enough to be used together with additional markers for AKI to better stratify renal injury 
(Pickering and Endre, 2016). 
In 2008, the FDA designated seven biomarkers of nephrotoxicity to test in animals and, on a case-by-
case basis, to be used in humans. These included urinary KIM-1, β2-microglobulin, cystatin C, clusterin, 
trefoil factor 3, albumin, and total protein. These markers, among others (e.g., urinary NGAL, urinary IL-
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18, and L-FABP - liver fatty acid binding protein), have been evaluated in many conditions but have 
rendered inconclusive results as a predictive model. In most cases, the data obtained with biomarkers 
tested in animals are compared to changes in serum creatinine (sCr) concentrations in humans, but results 
are questionable. In 2014, the NephroCheck test, which helps to determine if critically ill patients are at 
risk of developing moderate-to-severe AKI following 12-hour testing, was approved by the FDA. 
However, it is unknown at which time-point the measurement should be performed to ideally predict AKI 
(Alge and Arthur, 2015; Koyner et al., 2012; Zuk and Bonventre, 2016). Thus, there are few markers for 
progression of AKI to CKD. Moreover, this strategy of using biomarkers also serves to determine a 
specific point in the course of AKI when the predictive value of the biomarker should be tested (Chertow 
et al., 2005; Marx et al., 2018). 
AKI is an extremely heterogeneous and complex condition. Even though there is an effort to identify 
AKI biomarkers that could be used for risk assessment, diagnosis, severity, and/or outcome of AKI with 
high predictive power, an ideal, universal AKI marker is unlikely to be discovered. Thus, considering the 
heterogeneous nature of AKI, a complex multimodal approach, including a detailed risk assessment and 
the implementation of new biomarkers, is advisable to prevent and manage AKI (Meersch and 
Volmering, 2017).  
For this reason, several biomarkers that comprise the different aspects of AKI are required. Sensitive 
detection of an acute reduction in kidney function and injury in various renal structures, as well as the 
evaluation of the degree of renal injury, are the types of information provided by marker panels. Ideally, 
these markers should also be mediators of other disease pathways in AKI. Even better, these markers are 
the key to understanding the pathological mechanisms, to indicating the etiology of AKI, to providing 
references for future therapies, as well as to following therapy progress. Early biomarkers to estimate 
renal tissue damage is an advance that replaces the old low-sensitive methods for diagnosis by using 
better AKI criteria (Mehta et al., 2015; Schrezenmeier et al., 2017). 
AKI biomarkers may be used to reveal higher serum creatinine levels after ischemia reperfusion 
injury (IRI) and can also be used an early indication of the progression from AKI to CKD. This may also 
indicate that the process used was not as effective as intended. For instance, fibrosis is still found in 
patients, despite the reacquisition of normal biochemical parameters, such as plasma creatinine removal; 
progression to CKD is still the most frequent result (Block and Schoolwerth, 2006). 
KIM-1 is a type I cell membrane glycoprotein  with extracell immunoglobulin and mucin domains 
(Devarajan, 2008; Hillege et al., 2006; Ichimura et al., 2004). The mRNA and protein for KIM-1 are 
expressed at very low levels in the normal rodent kidney; however, expressions increase dramatically 
after an injury in the proximal tubule epithelial cells in postischemic rodent kidney and in humans during 
ischemic acute renal ups and downs of using KIM-1, and according to Medić et al. (2015) (Medić et al., 
2015), larger trials are still necessary before KIM-1 can be tested in broader clinical trials. Although 
KIM-1 is a sensitive and specific marker for kidney tubular injury, it is difficult to measure it in acute 
settings (Miao et al., 2017). 
By contrast, Ichimura et al. (1998) (Ichimura et al., 1998) demonstrated that human KIM-1 exhibits 
homology to HAVCR1, and studies using gentamicin (Campos et al., 2018; Silva et al., 2017), 
  
6 
 
amphotericin B (Grossi et al., 2017), and cisplatin (no publishing data) have shown that the genes 
HAVCR1 (KIM1) might be used as in vitro biomarkers of nephrotoxicity. 
To find new drugs for AKI and prevent its transition into CKD, it is crucial to better understand how 
tubular injury and repair work. Once this knowledge is acquired, it would be possible to use translational 
biomarkers to assess drug targets and their pathways. Furthermore, the expected biological effect of the 
drug can be revealed by specific biomarkers, i.e., whether the drug has reached the pathophysiological 
pathway for which it was developed and what is the expected clinical outcome (Block and Schoolwerth, 
2006; Kramann et al., 2015; Schrezenmeier et al., 2017).  
 
5. Preclinical studies for nephrotoxicity 
 
5.1. Animal models 
 
Animal models have been widely used to understand the pathogenesis and underlying mechanisms of 
renal disease. As shown in the FIG.1, mice and rats are the most commonly used to study nephrotoxicity 
and therapeutic targets, as well as to identify new biomarkers, mainly because these are easily bred and 
are relatively inexpensive to house and maintain (Camacho et al., 2016). Nonetheless, few advances have 
been achieved in understanding nephrotoxicity mechanisms or in identifying either a new biomarker or a 
panel of biomarkers. According to our search, monkeys are also used; however, regardless of the size and 
breed of the animals, results did not show a good predictability to identify adverse effect in humans.  
 
FIGURE 1 
 
In fact, the failure of existing animal models to accurately predict nephrotoxicity has been a major 
barrier to the development of safer drugs. Extensively studied for several decades, animal models of 
human AKI have, to date, yielded no specific therapy that benefits the human disease, either in preventing 
its occurrence, ameliorating its severity, hastening its recovery, or retarding the risk of ensuing CKD. 
Such inability to translate these models’ uncovered salutary strategies into therapies for human AKI has 
led to a questioning of the value of these models: specifically, their resemblance and fidelity to human 
AKI. Overlapping this kidney-centered discussion are broader debates in relevant biomedical 
communities, national as well as international, regarding a worrisome, relative lack of congruence of 
conclusions in preclinical studies and the slow pace of translating findings obtained in animal models into 
new therapies for human disease (Nath, 2015). 
Ischemia–reperfusion is one of the main causes of AKI; by definition, human AKI implies decreased 
GFR. Hence, conventional AKI models are mainly the result of kidney ischemia–reperfusion, exposure to 
endogenous or exogenous toxins and urinary tract obstruction (Sanz et al., 2017). However, this may not 
be the case for animal models if only one kidney is injured. Hence, despite the abundant literature on the 
pathogenesis of ischemia–reperfusion, no novel therapy has been able to be applied in clinical scenarios 
(Ortiz et al., 2015). 
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Exogenous drugs or poisons, as well as endogenous toxins, are widely used to stimulate AKI for 
their side or poisoning effects. Among these models, 6–20 mg/kg cisplatin can result in acute tubular 
injury within 72 h, whereas the administration of 40–200 mg/kg gentamicin in rats for 4–10 days can 
induce acute renal failure (Bao et al., 2018).  
Chemotherapy comprised three cycles of high‐dose (80‐100 mg/m2) cisplatin administered on days 
1, 22, and 43. Cisplatin is a drug widely used for chemotherapy (80‐100 mg/m2 – IV administered on days 
1, 22, and 43) to effectively treat various cancers and gentamicin is an aminoglycoside antibiotic (6-12 
g/day, IV administered, for 2-6 weeks) commonly used to prevent gram-negative bacterial infection. 
However, both drugs have limitations in clinical practice due to nephrotoxicity. For many years, 
nephropathy caused by cisplatin and gentamicin have been widely studied, but it is still unclear, although 
different models using different animals have been used and many hypotheses have been suggested 
(Hayward et al., 2018; Lavergne et al., 2018; Quintanilha et al., 2019; Uccelli et al., 2008). Nevertheless, 
these hypotheses do not fully reproduce human clinical diseases. Hence, we do believe new in vitro 
strategies are necessary to study the molecular mechanism involved in nephropathy so as to reach proper 
clinical diagnoses and implement effective therapeutic interventions. 
Actually, some AKI models in mice have been used with both advantages and disadvantages (Table 
1). Even so, models tend to have a high clinical relevance, for example, classical models contain a high 
knowledge background and are technically simple and reproducible. The types of models are incomplete 
and many details, such as model techniques and modeling time, are not mentioned. In addition, the 
majority of these have a variable response between models, expected acute renal necrosis is not always 
achieved,  AKI is not produced clinically and pathologically, surgery is required, reproducible outcome is 
dependent on accurate Ischemia/Reperfusion time, and the renal function can be compensated by a non-
ligated kidney (Bao et al., 2018). 
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Table 1: Advantages and limitations of conventional AKI animals models. 
Model Renal target Design Advantages Limitations 
Isquemia-
reperfusion 
Proximal 
tubule and 
endothelium 
Clamping time:  
30-45 min 
Reperfusion time: 
24-48 hours 
Pathology similar to 
human disease 
Requires surgery 
D
ru
g
 i
n
d
u
ce
d
 
Cisplatin 
Proximal 
tubule 
Sinlge IP injection  
(6-20 mg/kg)  
72 hours 
Pathology, timing 
and drug doses 
similar to human 
disease 
No clinical correlate 
Gentamicin 
Proximal 
tubule and 
glomerulus 
Serial IP injections  
(40-200 mg/kg/day)  
4-10 days 
Induces rapidly 
progressive CKD 
No fully reproduce 
human clinical 
diseases 
Aristolochic 
acid 
Proximal 
tubule 
Serial IP injections  
(5 mg/kg/day)  
5 days 
Induces rapidly 
progressive CKD 
No clinical correlate 
Folic acid 
Proximal 
tubule 
Single IP injection  
(250 mg/kg)  
24-48 hours 
Pathology findings 
similar to human AKI 
from other causes 
No clinical correlate 
Glycerol 
Proximal 
tubule 
Single IM injection  
(8 mL/kg of glycerol 
50%)  
24-48 hours 
Clinically relevant, 
resembling human 
rhabdomyolysis 
Severe and focuses in 
the symptoms, not the 
mechanism 
Warfarin 
Proximal 
tubule and 
glomerulus 
5/6 nephrectomy for 3 
weeks and 8 days on 
warfarin 
Useful to study AKI 
caused by 
anticoagulants 
Not guarantee the 
same mechanism 
IP, intraperitoneal; IM, intramuscular. 
 
Aristolochic acid (AA) and high dose folic acid (FA) are also frequently used to study AKI-CKD 
transition, with AKI models developed by warfarin and glycerol (Bao et al., 2018).  
Nephrotoxicty caused by AA was first reported in Belgium in a group of patients who ingested 
weight loss pills containing extracts of Chinese herbal powdered roots(Vanherweghem et al., 1993). The 
findings in humans are supported by laboratory animal studies showing that oral exposure to aristolochic 
acids caused tumors in the urinary tracts of various animal species. Although this model showed good 
results it did not work for other drugs. In 2001, the U.S. Food and Drug Administration (FDA) advised 
consumers to stop using any products that may contain aristolochic acids, after seeing an increase in 
nephropathy, or kidney disease, among users (Food and Drug Administration, 2001).  
Fink et al. (1987) (Fink et al., 1987) demonstrated that single intravenous doses of FA in rats causes 
direct nephrotoxic effects; hence, it has been used to study AKI-CKD transition. Some studies have used 
intraperitoneal injection (Linkermann et al., 2014, 2012; Martin-Sanchez et al., 2017). However, FA is the 
synthesized form of folate present in fortified foods and supplements, such as grains, and has a higher 
bioavailability than naturally occurring folate (Khan and Jialal, 2019).  
Thus, AA and FA are used at low doses for oral administrations in human and at high dosages and 
intravenous and peritoneal doses when studying nephrotoxicity in animals. Hence, AA and FA do not 
represent good models, since the profiles for causing nephrotoxicity are completely different. 
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Warfarin (WRN) therapy can result in AKI by causing glomerular hemorrhage and renal tubular 
obstruction by red blood cell (RBC) casts (Brodsky et al., 2009). Analysis of more than 15,000 warfarin-
treated patients showed that WRN affects approximately 33% of CKD patients and 16% of non-CKD 
patients who experienced an international normalized ratio > 3.0. This study also identified that mortality 
rates in patients with WRN was significantly higher than in patients without WRN (Brodsky et al., 2011).  
However, excessive anticoagulation in control animals was not associated with changes in creatinine 
levels, and renal morphology was normal. Therefore, Ware et al. (2011) (Ware et al., 2011) developed a 
new method to study nephrotoxicity using an excessive amount of warfarin combined with a 5/6-
nephrectomy model. Although this method could cause functional and morphological damage of the 
remnant kidney, it does serve to demonstrate the effect. Nevertheless, it does not guarantee the same 
molecular mechanism responsible for nephrotoxicity, which is the main element to be discovered. 
 AKI is also a common complication of rhabdomyolysis and accounts for the high mortality (Bao et 
al., 2018; Elterman et al., 2015; Zhang et al., 2012). To reproduce the typical symptoms observed in 
humans, rats or mice are deprived of water for 24 h, after which a 8–10 mL/kg dose of 50% glycerol is 
administrated in the hindlimb muscle (Geng et al., 2015; Kim et al., 2014). We do not believe glycerol 
could be a good model, given that the model is focused on the symptoms, which is not the main point of 
our study. In addition, glycerol is used in human food at low doses. Thus, it does not represent a good 
model to study nephrotoxicity. 
Mechanisms of disease generation and progression in AKI and CKD have yet to be fully understood 
(Singh et al., 2013; Tampe et al., 2017). Although several clinical studies have investigated early stage 
predictive biomarkers of kidney disease, few have been applied in clinical practice (Endre and Pickering, 
2013). CKD models can include mainly renal mass reduction, diabetic nephropathy, hypertension 
glomerular injury, IgA nephropathy, polycystic kidney disease, and chronic tubulointerstitial nephritis 
(Table 2). 
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Table 2: Advantages and limitations of experimental CKD animals models. 
Pathology Model Transition 
AKI-CKD Advantages Limitations Comments 
Renal mass reduction 5/6 nephrectomy (rats) Depends on the 
mice strains Equivalent to humans 
Two surgery requires. The second one having a high mortality rate, 
especially in mice, and requiring technical expertise; mice strains are 
differentially responsive to renal mass reduction with respect to 
CKD progression; it is irreversible and the amount of kidney left to 
study is small and may be distorted by surgical procedure 
No clinical translation of 
successful 
Diabetic 
Nephropathy 
Streptozotocin mice/rats; 
NOD mice BB-DP rat; ob/ob 
mice db/db mice; STZ-eNOS-
/-; db/db-eNOS/mice 
No 
Gene modified; commercially available; 
available on multiple strains; useful to study 
mechanisms of diabetic nephropathy. 
Reproduce human physiopathology 
None of the many animal models perfectly replicate the human 
disease; expensive; some strains are infertile; cause modest 
albuminuria without decreased GFR 
No clinical translation of 
successful 
Hipertensive 
Nephropathy 
SHR rats+UNX; angiotensin 
II infusion models 
Depends on the 
dose/time 
Highly relevant to hypertension nephropathy; 
useful to study AngII effect over kidney 
SHR rats are more resistant to streptozotocin-induced diabetes; 
uninephrectomy is required to promote significant kidney injury; no 
progressive GFR loss; higher dose or long exposure time periods 
increase serum creatinine levels; high cost; slow progression 
No clinical translation of 
successful; long exposure 
time periods stress animals 
Acquired Glomerular 
Injury 
Focal segmental 
Glomerulosclerosis: 
adriamycin (rat, mice) or 
puromycin (rat) 
Depends on the 
strains Mimic acute glocmerular injury 
Usually no adequate reproduction of slowly progressive human 
disease 
No clinical translation of 
successful NOD 
IgA Nephropathy ddY mouse, HIGA mice; 
Uteroblobin-deficient mice  Reproduces human pathology 
Mild disease development usually without progression towards end-
stage renal disease; no progressive GFR decrease 
No clinical translation of 
successful 
Polycistic Disease Genetically engineered mouse 
model 
Yes, but no 
specific to renal 
disease 
Useful to study PKD mechanisms and to find 
therapeutic targets; new insights into the 
molecular mechanisms of cystogenesis and 
associated progression of CKD; resulted in 
regulatory approval for Tolvaptan in Japan for 
human ADPKD 
Mouse models usually lack the variety of human phenotypes 
ARPKD mouse models 
usually lack the variety of 
human phenotypes 
Chronic 
Tubulointersticial 
Nephritis 
Simple, dose-dependent 
decreased GFR; Possibly 
reversible (rats) 
 
Model no 
specific for 
human 
Simple, dose-dependent decreased GFR; 
possibly reversible 
Adenine-ged male rats had a more severe decline in kidney; models 
CKD extrarenal complications; function and molecular changes 
Adenine intoxication is not an 
issue in human 
Hereditary 
Glomerular Injury 
Pkd1 or Pkd2 gene 
engineered; Col4a43 gene 
knockout mouse; Alport 
syndrome 
 
Depends on the 
strains 
Reproduce features of human disease, 
including progressive GFR loss; develop 
proteinuria and renal failure 
Difficulty to translation of genetic findings into improved patient 
care; high costs 
Resulted in clinical 
recommendations 
Stone Disease Natural development (dogs 
and cats) No information Without external factors to cause disease Few studies Long-term 
 
GFR glomerular filtration rate; SHR, Spontaneously Hypertensive rat; BB-DP, BioBreeding-diabetes prone; nod, nonobese diabetic; ob/ob, obese; db/db mouse, type 2 diabetes; DBA/2J, model 
for congenital experimental glaucoma; STZ, streptozotocin; Enos, endothelial nitric oxide synthase; UNX, uninephrectomy; ddY mouse, outbread; HIGA, Nephropathy with Hyperserum IgA; 
pkd, polycystic kidney disease; COL, collagen genes.
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Renal mass reduction (remnant kidney model) is one of the most widely used models to study CKI. 
Subtotal (5/6) nephrectomy has been a mainstay of studies of progressive CKD.  The right kidney is 
removed and the upper and lower poles (2/3 of the left kidney) are resected after ligation of the left renal 
artery. After surgery, activation of the renin-angiotensin system (RAS) can cause glomerular 
hypertension/hyperfiltration (Bao et al., 2018; Ergür et al., 2015; Ortiz et al., 2015; Tapia et al., 2012). 
Glomerular injury may be acquired or hereditary. Acquired diabetic nephropathy (DN) is the leading 
cause of ESRD. There are many rodent models for diabetic nephropathy; however, none of them perfectly 
mimics the human disease (Deb et al., 2010). The Animal Models of Diabetic Complications Consortium 
(AMDCC) defines the ideal rodent model of human diabetic nephropathy and complications (Kitada et 
al., 2016; Kong et al., 2013). Several models of gene targeting have reproduced mutations to generate 
murine models of hereditary podocyte-based nephropathies, including focal segmental glomerulosclerosis 
and Alport syndrome (Ortiz et al., 2015). Hypertension-induced renal injury is usually investigated by 
using spontaneous hypertension. Additionally, uninephrectomy is required to promote significant kidney 
injury in the form of albuminuria without reduced GFR (Nishimura et al., 2018). Chronic exposure to 
pressure-increasing doses of angiotensin II in rats and mice caused renal dysfunction (Ruiz-Ortega et al., 
2006).  
Focal segmental glomerulosclerosis (FSGS) is a common primary glomerular injury, characterized 
mainly by podocyte loss, glomerular fibrosis, and marked proteinuria (Fogo, 2015). Although there is 
currently no primary FSGS model available, several secondary FSGS models have been established. Non-
genetic models mimic acute glomerular injury but not the spontaneous slowly progressive focal segmental 
glomerulosclerosis observed in the clinic. Experimental podocyte depletion, using adriamycin or 
puromycin aminonucleoside, in turn leading to CKD, emphasizes the key role of podocytes in the 
preservation of the renal function (Daehn et al., 2014; Ortiz et al., 2015). 
IgA nephropathy (IgAN) is the most common human glomerulonephritis, but no specific therapy has 
been discovered. However, none of these models enabled the identification of the factors that control the 
transition between disease onset and progression to ESRD. Thus, the underlying mechanism of IgAN is 
still not fully understood (Bao et al., 2018; Ortiz et al., 2015). 
Polycystic kidney disease (PKD) includes a group of human monogenic disorders inherited in an 
autosomal dominant (ADPKD) or recessive (ARPKD) fashion. Genetically engineered mouse models, in 
which disease-causing genes were targeted, now mimic human ADPKD, ARPKD, and atypical PKD. 
Those models have already provided new insights into the molecular mechanisms of cystogenesis and the 
associated progression of CKD. However, ARPKD mouse models usually lack the variety of human 
phenotypes (Ortiz et al., 2015). 
Primary chronic tubulointerstitial nephritis is associated with an immune-mediated infiltration of the 
kidney interstitium by inflammatory cells, which may progress to fibrosis. This is characterized by 
tubular atrophy, interstitial fibrosis, and interstitial inflammation in the absence of significant glomerular 
disease. Most animal models of chronic tubulointerstitial nephritis are secondary to ischemia, proteinuria, 
AKI, or other primary kidney diseases (Joyce et al., 2017; Ortiz et al., 2015). Thus, the processes 
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involved are different and do not demonstrate similar mechanisms; hence, it does not represent a good 
model. 
In addition to the animals already mentioned dogs and cats also have been suggested to study the 
calcium oxalate stone formation, considering that a naturally occurring animal model could be more 
useful.  This strategy could represent a good model; however, the pathologic and etiologic mechanism 
surrounding calcium oxalate nephrolithiasis is incomplete (O’Kell et al., 2017). 
Thus, despite the valuable new insights into kidney disease gained from existing models, many do 
not fully reproduce human clinical diseases.  In the AKI, models are not stable and reproducible, while in 
the CKD, the disease is quite complex (Bao et al., 2018). However, in addition to each model's specific 
limitations, all animal-model research into human diseases is ultimately restricted by the need to translate 
findings across species. This calls for the wider use of human-based models to complement and reduce 
the use of experimental in vivo research (Fonseca et al., 2017). 
In this scenario, we do believe that new strategies and models without animals are required to better 
mimic processes involved in AKI and CKD. These models must mainly address molecular mechanisms, 
since the mere understanding of them may help to develop therapeutic interventions and clinical 
diagnoses, as well as to identify new biomarkers for nephrotoxicity. Hence, we also believe that new 
strategies are paramount for advances in this area. Moreover, alternative methods, such as those addressed 
in this review, represent important tools that can shift the paradigm of nephropathy and the way new, 
more effective, and safer molecules can be developed. 
 
5.2.  In vitro models 
 
In vitro toxicity studies, whether cell or tissue, have been used to study the mechanisms of action 
and toxic effects of drugs in order to assess efficacy and safety in humans regarding exposure to 
xenobiotics, and may also help to classify them according to their toxic capacity. The knowledge of the 
mechanism of toxic action involving a xenobiotic is of paramount importance, since it provides 
significant aid in the evaluation of predictive values, in addition to improving the selection of new drugs 
to treat specific pathologies (Eisenbrand et al., 2002; Descotes, 2003; Bernauer et al., 2005). 
The number of in vivo studies has grown proportionally to in vitro studies (FIG.2) according to our 
search. To find these numbers we used the keywords listed below. 
 
FIGURE 2 
 
Despite this, such models have demonstrated limitations in generating knowledge of nephrotoxic 
processes in humans. By contrast, there is an increasing demand for new methods that refine, reduce, and 
replace animal use. Cell culture techniques are extremely relevant tools for in vitro studies of 
nephrotoxicity. The number of studies with animal models and in vitro renal toxicity has grown in the last 
20 years. Despite this increase of both strategies, no reported results have provided a better understanding 
of nephrotoxicity mechanisms (FIG.2).  
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It is difficult to study specific epithelial cell types because the renal cortex carries a heterogeneous 
population of renal tubule segments. Fortunately, improvements in the methods used to grow 
homogeneous cultures of kidney cells allow one to access proper cells over different portions of the 
nephron. Other possibilities are the 3D printing of scaffolds to test the efficacy of new drugs, which will 
be different in scale and throughput from the assays used in the initial toxicological screening of 
chemicals (Innovate UK, 2015).  
Regardless of these advances, the kidneys produce very complex structures with blood filtration and 
urine re-absorption units needed for their function and homeostasis. It will also be highly important to 
consider the quality control of kidney organoids for disease modeling, added to the potential sources for 
developing kidney regenerative therapies. Conversely, there is currently no consensus regarding the 
methods that should be used for the evaluation of the quality of kidney organoids, mainly in terms of their 
functional characterization (Morizane and Bonventre, 2017). 
Recently, the mouse ENCODE Consortium reported that, while there are many similarities between 
human and mouse genomes, there are important differences as well. Consequently, animals are not good 
models for nephrotoxic effects in humans. Many discrepancies in DNA and differences in gene 
expression patterns have been found, potentially restricting the usefulness of some disease models based 
on mice (Yue et al., 2014).  More than 160 inherited genetic kidney diseases are now known.  
Alternatively, by establishing human induced pluripotent stem cells (hiPSCs) from patients with a 
given genetic disease, such as degenerative disorders and cancer, it might be possible to study customized 
disease mechanisms and to perform drug screening in vitro instead of using animal models. Most 
importantly, updated advances in genome editing have provided new approaches to modeling genetic 
kidney diseases by using human pluripotent stem cells (hPSCs) in vitro (Cheng et al., 2014; Dakhore et 
al., 2018; Devuyst et al., 2014; Stergachis et al., 2014). 
In addition, the market potential for NATs (Non-Animal Tests) is enormous. Approximately $100 
billion was spent on R&D in 2014 by the top 25 pharmaceutical companies (based on recorded global 
sales for 2014) and a recent survey of the members of Pharmaceutical Research and Manufacturers of 
America estimated that more than 20% of total R&D expenditure was on preclinical research (Innovate 
UK, 2015; Pharmaceutical Research and Manufacturers of America, 2013). 
In the long term, there is the potential to use NAMs (Non-Animal Models) to support the 
development of personalized medicines through the use of human-based approaches that will enable the 
identification of the possibility for side effects caused by drugs, or variations of efficacy in the 
population. The selection of patients on the basis of their predicted response allows a drug to continue 
through its development into clinical use in circumstances where its progress would otherwise have been 
suspended. This could bring enormous benefits to both patients and companies (Innovate UK, 2015). 
In addition, there is an increasing demand for new methods which refine, reduce, and replace animal 
use. Cell culture techniques are extremely relevant tools for in vitro studies of nephrotoxicity. The 
number of studies with animal models and in vitro renal toxicity has grown in the last 20 years. And 
despite this increase in both strategies, it has not resulted in a better understanding of nephrotoxicity 
mechanisms (FIG.2).  
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6. New technologies 
 
While in vitro models have helped us to understand nephrotoxicity mechanisms, it is paramount to 
use new technologies, such as omics (transcriptomics, proteomic, and metabolomics), bioinformatics 
platforms, CRISPR/Cas9 genome-editing and in silico modeling to advance this process. As shown in 
FIG.3, these new technologies have been increasingly applied to study renal toxicity. 
 
FIGURE 3 
 
6.1. Omics technologies 
 
Omics technologies include transcriptomics, proteomics, and metabolomics and are methodologies 
applied for biomarker identification useful in understanding the mechanisms of nephrotoxicity. Such 
technologies offer unbiased approaches to identify new biomarkers of AKI. Circulating or urinary 
microRNAs are being evaluated, and kidney-specific DNA methylation patterns are also being analyzed. 
Researchers have also been paying attention to urinary extra cell vesicles, which contain mRNA, 
microRNA, and proteins that mimic the cell physiology and pathophysiology along the nephron. The 
components of urinary extracellular vesicles are a source of information about disease pathogenesis, and 
they may serve as diagnostic and prognostic biomarkers, since they may enable target identification for 
drug discovery or provide evidence of biological activity in response to therapeutic agents. Among other 
objectives, omics studies seek to identify those that are mainly descriptive in nature, through the 
integration of experimental approaches and new computational modeling, such as in systems genetics, 
which will be generated in order to help identify marker sets to guide diagnoses, monitor disease 
progression, and identify new therapeutic targets (Ho et al., 2014; Kumar et al., 2014; Marx et al., 2018). 
The European Consortium for High Throughput Research in Rare Kidney Diseases (EURenOmics) 
has been working on a cohesive bioinformatics platform to study rare nephropathies. Additionally, a renal 
phenomenon database is being created, using the Human Phenotype Ontology website. The phenotype 
information will be linked to genomic, transcriptomic, proteomic, and metabolomics studies, omics 
datasets, and the public domain knowledge-base in a systems biology approach to identify molecular 
pathways associated with phenotypic features (Levy and Myers, 2016). 
This situation thus becomes a great opportunity to advance in vitro studies for renal disease by 
analyzing gene expression. A bioinformatics platform will be an important tool to identify biomarkers 
that could be paramount in developing new medicines as well as in identifying nephrotoxicity and 
stopping the processes of AKI and CKD. Bioinformatics platforms are able to respond to such challenges 
as renal disease.  
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6.1.1. Transcriptomics  
 
Studies on transcriptional profiling have revealed molecular markers and potential regulatory 
pathways of renal repair. A few key markers become active on the developmental pathways that have 
been reported during repair. By using high-resolution technologies, such as RNA sequencing and 
translational profiling specific to cell compartments within the kidney, further insights into injury and 
repair processes will be gained through the study of repairing transcriptome and cell-specific translatome. 
An enhanced understanding holds promise for both the identification of modern therapeutic targets and 
biomarker-based evaluation of the damage-repair process (Kumar et al., 2014). 
Both proximal and distal tubular epithelial cells mount an acute transcriptional response to ischemia 
reperfusion injury (IRI). The earliest genes to be induced after in vivo injury (within 4 h after injury) 
include Fos, Jun, and Egr1 (Ouellette et al., 1990). Fos is induced predominantly in the thick ascending 
limb (TAL) (Witzgall et al., 1994). The latter observation suggests that the distal tubule, in addition to the 
proximal tubule, also senses the acute insertion. Subsequent microarray-based gene expression profiling 
studies encountered a similar immediate-early response, including Fos and Egr1, after IRI (Supavekin et 
al., 2003; Yuen et al., 2006). It is possible to identify toxicity on proximal and distal tubules, which will 
create an enormous advantage. Consequently, gene expression studies using tubular and renal cells may 
help to identify earlier nephrotoxicity (Kumar et al., 2014). 
Adler et al. (2016) showed that primary human proximal tubular epithelial cells (HPTEC) are a good 
in vitro model for screening for renal toxicity because they have differentiated epithelial cell 
characteristics. In addition, HO-1 expression proved to be a better option than currently used to predict 
toxicity in HPTEC, especially when combined with the total number of cells in the same assay. In 
addition, the approach used by the authors can be used to screen a large number of compounds besides 
can be used in combination with existing cytotoxicity assays (Adler et al., 2016). 
The understanding of how the several cell types in the kidney communicate, in order to regulate 
the intrinsic repair mechanisms and their contribution to post injury fibrosis, remains a substantial 
challenge. Nonetheless, a continued focus is still placed on cell-type–specific signatures and a broadening 
of analysis beyond early injury, which in turn makes it feasible to provide important new insights. 
Clearly, the major clinical objective is to develop new analytical tools to diagnose both short- and long-
term outcomes, as well as to develop new therapeutic strategies to improve existing repair processes and 
reduce the long-term risk of CKD after AKI (Devuyst et al., 2014). In sum, all of these strategies could 
help to develop new agents to treat renal disease. 
 
6.1.2. Proteomics 
 
Proteomics is considered one of the most promising ‘omics techniques for biomarker discovery in 
AKI, as it may identify specific molecular targets for early injury in different renal compartments. Almost 
all human diseases are characterized by a complex panorama at the molecular level, and it is imperative to 
acquire a global proteome picture to depict pathways and proteins with pivotal roles in pathogenesis. 
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Proteomics studies have indicated that a single biomarker cannot fully account for the complexity of 
human diseases, and thus it is preferential to use biomarker panels.  
Hence, it is thought that proteomics is a good tool for discovering and identifying new premature 
biomarkers. The main target of proteomics is to characterize the information flow within the cell and the 
organism, through protein pathways, interactions and networks, thereby allowing a hypothesis-free 
identification of disease biomarkers (Rosner and Okusa, 2006). The search for biomarkers using urinary 
proteomics approaches has proven to be effective in CKD, diabetic nephropathy, acute kidney injury, 
ureteropelvic junction obstruction, vesicoureteral reflux, renal Fanconi syndrome, acute renal allograft 
rejection, cancer, diabetic nephropathy, chronic rhinosinusitis, atherosclerosis and calcific aortic valve 
disease, and posterior urethral valves (Di Carlo et al., 2018; Marx et al., 2018; Mulligan et al., 2018; 
Neufeld et al., 2014; Patti et al., 2012; Salvadori and Tsalouchos, 2017; Van et al., 2017). 
 
6.1.3. Metabolomics 
 
Metabolomics is defined as the analysis of molecules smaller than 1,000 Da, which are transformed 
as a result of, and in support of, an organism’s metabolism. The metabolome accounts for a complete set 
of metabolites that can be produced and consumed by organisms (Alonso et al., 2015; Patti et al., 2012). 
The results of metabolomics experiments constitute big data and require sophisticated data handling 
strategies and advanced statistical tools. In addition, before any statistical analysis, data preprocessing 
must take place to ensure the best possible results from the applied statistics (Marx et al., 2018). Spectral 
alignment, normalization, transformation, and scaling are indispensable stages in metabolomic data 
preprocessing. Data normalization is required for accurate metabolite quantification. To normalize data, a 
common method is based on endogenous metabolites, such as urinary creatinine. However, creatinine 
itself may be somewhat variable, and subject to variation owing to diseases such as AKI (Alonso et al., 
2015; Frank  Dieterle et al., 2006; Marx et al., 2018). 
The potential to identify drug targets from metabolomics will be amplified by the coordination of 
efforts to analyze samples of human kidney tissue and other biomaterial, such as urine and blood, by 
using state-of-the-art genomic, proteomic, and metabolomic approaches, together with detailed patient 
phenotyping and the use of existing biomarkers to discover and qualify new therapeutic purposes. Genetic 
data should be linked to existing phenotypic information or generated from customized human tissue 
models, by using induced pluripotent stem cells and targeted mutation, followed by differentiation to 
human kidney tissue. To give support to these efforts, enhanced disease prototypes are needed to reflect 
the complexity of CKD (Nicholson and Lindon, 2008; Patti et al., 2012). 
Equally challenging is the multifactorial origin of AKI and the fact that the changes of molecular 
expression induced by AKI are difficult to distinguish from those of the diseases associated with or 
causing AKI, such as shock or sepsis(Marx et al., 2018). In the past, these experiments were focused on a 
single metabolite that was attributed to a specific disease or enzymatic reaction (German et al., 2005). 
Nowadays, such technologies as GC/MS (gas chromatography-mass spectrometry) and computational 
tools allow for a more extensive and wide-ranging investigation of many metabolites within a single 
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measurement, providing a broader insight into mechanisms of diseases (Marx et al., 2018). For this 
reason, it is very important to employ a panel of biomarkers. 
New and cutting-edge techniques have been, and continue to be, developed; the challenge with the 
present status of metabolomics is its transition to clinical use. Integrating metabolomic data with other 
omics data for the purpose of drug discovery, and development is one direction in which this field may 
proceed (Kell and Goodacre, 2014; Robertson and Frevert, 2013). 
The low sensitivity of current clinical markers (serum creatinine and blood urea nitrogen- BUN) in 
early stages of the development of acute kidney injury limits their utility. Rapid LC/MS (liquid 
cromatography-mass spectrometry)-based metabolic profiling of serum was demonstrated in 
a key study showing that metabolomics could provide new indicators of AKI. Currently, omics 
technologies provide a great opportunity for research in rare renal diseases, as it is possible to probe the 
diseased organ directly (Sun et al., 2012). Hence, we believe it is important to compare results obtained 
from patients and to evaluate them using cells, mainly because there are several different types of renal 
disease. This would thus be a safer strategy for using clinical results as a starting point. 
 
6.2. CRISPR/Cas9 genome-editing 
 
The fast advancement of genome‐editing technologies has provided new pathways in the study of 
the genetic basis of human diseases and in the development of targeted therapeutic strategies that would 
not have been possible with traditional pharmacological drugs. Chemical toxicants act by many different 
mechanisms, however, the genes involved in adverse outcome pathways (AOPs) and AOP networks are 
not yet characterized. Functional genomic approaches can reveal both toxicity pathways and susceptibility 
genes, through knockdown or knockout of all non-essential genes in a cell of interest, and the 
identification of genes associated with a toxicity phenotype following toxicant exposure (Lin and 
Musunuru, 2016; Shalem et al., 2014; Shen et al., 2015). 
In this environment, new strategies could improve the engineering of genome‐editing tools, and 
appropriate regulatory practices, together with genome editing, will accelerate discoveries in basic 
science and clinical translation, which will in turn aid in the process of identifying new biomarkers to 
become more robust. Hence, advances in genome editing with CRISPR/Cas9 will promote the use of 
kidney organoids to study inherited genetic kidney diseases (Lin and Musunuru, 2016). 
The potential use of kidney organoids derived from hPSC combined with genome engineering 
technologies, particularly the CRISPR/Cas9, is a novel approach for the targeted modification of the renal 
epigenome to study renal organ dysfunction, such as CKD (Hurtado Del Pozo et al., 2018). In addition, 
this technology could be further used to produce kidney phenotypes. 
 
6.3. In silico 
 
In silico, or computational, approaches to predicting and identifying compounds associated with 
kidney disease are based on the use of existing data and the ability to draw chemistry-based inferences 
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from those data (Cronin and Madden, 2010). The concepts are relatively trivial in that, should data of 
acceptable quality be available for a compound, then there is no need for further testing. If no suitable 
data are available for a compound, then inferences can be made from it, e.g., making an analogy with 
similar compounds or identifying chemical / molecular features that may be indicative of the ability to 
cause disease. All of these resources together form a battery of computational approaches, or even of a 
compound, that can shed light on the disease-causing potential (Cronin and Yoon, 2018). The general 
availability of data related to the ability of a compound to cause damage to the kidney has been reviewed 
by Pletz et al. (2018) (Pletz et al., 2018). The resources can be classified according to the type of data 
they represent. The most relevant for human risk assessment are those for the effects of compounds in 
humans; these are available as part of clinical trial data or from reports of adverse drug reactions. 
Websites, such as www.clinicaltrials.gov, are useful to retrieve such data. While potentially relevant, they 
can only be used for the drugs to which they relate and lack consistency between clinical trials. To 
develop and evaluate in silico models, the results of animal tests done in the past are now useful, 
particularly low-dose chronic toxicity testing that show the superior predicting power of in silico models. 
Several resources have been compiled of repeated dose toxicity values and are freely available. These 
become useful in understanding and evaluating effects to the kidney when they record organ-level effects. 
The COSMOS database was developed specifically to achieve this and can be searched for organ-level 
toxicity, including effects to the kidney and bladder (Mostrag et al., 2018). Other similar databases of 
repeated-dose toxicity data include REPDOSE (Bitsch et al., 2006) and HESS (Sakuratani et al., 2013). 
Other significant data resources of repeated-dose toxicity values that may require licensing and/or 
payment include Chemtunes (MN-AM, https://www.mn-am.com/products/chemtunes), Vitic Nexus 
(Lhasa Ltd, https://www.lhasalimited.org/products/vitic-nexus.htm), and LeadScope Toxicity Database 
(Leadscope Inc, http://www.leadscope.com/product_info.php?products_id=78). It is important to note 
that while these data resources may shed light on which compounds may promote disease, or damage, to 
the kidney, they were not developed specifically for this purpose.  
There are fewer databases for in vitro data. However, one important resource that will aid in 
understanding, from the mechanistic point of view, is the compilation of the United States Tox21 
initiative. Tox21 set about to screen large numbers of compounds (currently over 10,000) with high 
content assays, some of which are relevant to the effects and mechanisms of kidney disease and 
damage(Richard et al., 2016). This immense and freely accessible resource is available through the US 
EPA’s Chemistry Dashboard(Williams et al., 2017). The Chemistry Dashboard is a cutting-edge and 
rapidly evolving resource for in silico assessment. It enables a user to input a chemical structure, retrieve 
existing (in vivo and Tox21) data, make predictions, and build knowledge about a substance. It is 
currently focused on a number of environmental and human health effects and could be applied to provide 
information on kidney disease if used appropriately, i.e., the data can assist in the identification and 
rationalization of chemicals associated with disease. Another important in silico tool that brings together 
data through the development of chemistry-based groups is the OECD QSAR Toolbox 
(https://www.qsartoolbox.org/). Designed for grouping and read-across to allow for data gap filling, the 
Toolbox includes access to mechanistically based profilers to find similar molecules.  
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One of the most powerful methods to use existing data to make predictions for compounds with no 
data (the aforementioned process of data gap filling) is to form groups of similar compounds and “read-
across” data from one molecule to another (Patlewicz et al., 2018). The use of the read-across paradigm 
has seen growth in recent years, most notably due to its application in the European Union’s Registration, 
Evaluation, Authorization and restriction of Chemicals (REACH) legislation (Spielmann et al., 2011). 
The identification of similar compounds is a broadly applied concept and requires a certain basis. One 
approach has been to use markers of organ-level toxicity to define similarity (Cronin and Richarz, 2017). 
What seems particularly relevant here are the chemistry-based structural alerts or biomarkers for kidney 
disease. Thus, should compounds be associated with the same chemistry alerts or biomarkers, then 
similarity in activity may be assumed, i.e., a prediction of harm can be made by analogy to the similar 
substance. While conceptually simple, there are numerous caveats to the approach and care must be taken 
(Schultz and Cronin, 2017). One means of providing relevance from the in silico side is to ensure that the 
alerts are anchored on a mechanistic basis and specifically to relevant AOPs (see section below).  
The logical identification of structure-activity relationships related to kidney disease, i.e., the sub-
molecular features intimately associated with damage, has enabled the concepts of structural alerts to be 
defined. Such alerts are easily coded into software. Some structural alerts for kidney damage are available 
in the literature; for example, Myshkin et al. (2012) (Myshkin et al., 2012) published alerts for a number 
of effects. Efforts are currently underway to rationalize the small number of publicly available structural 
alerts for harm caused to the kidney and to add new alerts where they are missing. This work is being 
supported by a compilation of over 200 compounds known to cause harm to the kidney (Pletz et al., 
2018), which have assisted in the evaluation of existing alerts and will enable efficient screening of new 
molecules for these effects.  
Historically there have been many efforts to form quantitative associations between chemical 
structure and biological activity – the development of the so-called Quantitative Structure-Activity 
Relationships (QSARs) (Cronin and Madden, 2010). It is fundamental that QSARs require suitable data 
for development and, ideally, should be mechanistically based. As a result, particularly of the need for 
robust data sets, there have been relatively few QSAR models developed for nephrotoxicity; available 
models have been reviewed by Pletz et al. (2018) (Pletz et al., 2018). For instance, Lei et al. (2017) (Lei 
et al., 2017) used machine learning approaches to develop models for damage to the urinary tract. While 
some progress has been made, the development of QSARs for the full suite of harmful effects to the 
kidney is limited at the current time, but it can be expected to improve due to the better access to reliable 
data for modeling.  
Using human renal proximal tubular cells (PTC) and a set of 44 compounds, subdivided into PTC-
toxic, non-PTC-toxic and non-nephrotoxic compounds, Su et al. (2016) described an approach based on 
high-throughput imaging, phenotypic profiling and machine learning methods to predict human 
nephrotoxicity. This approach does not require characterization of injury mechanisms and is capable of 
identifying structurally distinct xenobiotic-induced nephrotoxicity that lead similar phenotypic endpoints 
as from six sets of nuclear and actin cytoeskeletal features with high efficiency and accuracy (Su et al., 
2016).  
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In addition to using information from chemistry for modeling, according to Soo et al. (2018) (Soo et 
al., 2018), integration of information obtained from in vitro models into computational algorithms that 
incorporate patient-specific physiological parameters will not only reduce late drug loss from the 
development pipeline, but also facilitate the development of safer drugs and improve compound 
management of clinically important adverse nephrotoxic effects. 
 
6.4. Stem cells 
 
Stem cell therapy is an innovative approach to ameliorate IRI due to its antioxidative, 
immunomodulatory, and anti-apoptotic properties. However, the majority of the studies are confined to 
experimental animal models, although, several studies have investigated Mesenchymal stem cells -based 
therapies for both acute and chronic kidney disease in clinical trials.  Hence, it is paramount to understand 
the biological effects and mechanisms of action of stem cell therapy to improve its therapeutic benefits. In 
addition, more translational studies are needed to provide a more comprehensive understanding of stem 
cell-based therapies and to ensure their safety for future clinical applications (Lee et al., 2019; Li and Li, 
2019).  
 
7. New models 
 
New models such as organoids and 3D bioprinting also are important tools which may help us to 
understand nephrotoxicity mechanisms. 
 
7.1. Organoids 
 
Nephrons are complex architectural 3D structures. Hence, to recapitulate these structures ex vivo, the 
development of 3D culture systems is required. Organoids are 3D organ-like tissues that mimic in vivo 
organs structurally and functionally in culture plates. Kidney organoids derived from hPSCs are an 
attractive approach for studying mechanisms of human inherited kidney diseases, which might be applied 
to more common diseases as well as to the development of new drugs using human tissues, which may 
facilitate the translation of the findings obtained with this methodology to humans. However, to optimize 
this approach, differentiation protocols, genetic background, and epigenetic variation need to be 
considered in depth when disease phenotypes are analyzed in kidney organoids (Morizane and Bonventre, 
2017). 
One goal of hPSC studies is to regenerate the kidney function. Kidneys form complex structures with 
blood filtration, and the urine re-absorption unit is paramount for their functioning and homeostasis. 
There are many challenges in the use of organoids to generate functional bioengineered kidney tissues. 
Vascularization of kidney organoids needs to be induced in an organized way to direct blood flow from 
arteries in order to drain into venous structures. This represents one of the great challenges related to 
vascularization (Morizane and Bonventre, 2017).  
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7.2.  3D bioprinting 
 
In addition, the use of 3D bioprinting has proven to be an option to study nephrotoxicity, namely a 
functional bioengineered kidney with vasculature, multiple cell types, which include proximal tubular 
cells, and an extracell matrix. A new system is being used to generate heterogeneous structures in 3D that 
enable the perfusion of liquid into lumens lined with vascular or tubular cells. It may be employed to 
mimic blood flow and intratubular flow in vascular and tubular channels (Kolesky et al., 2016, 2014; 
Morizane and Bonventre, 2017). 
 
8. Adverse Outcome Pathways (AOP)  
 
The AOP framework is a systematic, transparent approach used to organize existing toxicological 
knowledge and translate mechanistic information to adverse effects at higher levels of organization based 
on causal relationships between endpoints (FIG. 4). As such, the AOP framework has been proposed as a 
means to relate alternative types of data (in silico, in vitro and in vivo, biomarker-type data) to endpoints 
of concern to chemical risk assessors (e.g., survival, growth, and reproduction). This application in the 
regulatory field is timely given the current momentum to move toxicology from broadly empirical in vivo 
assessments of unique chemical effects to predictive approaches that make use of newer tools and 
alternative data (Ankley et al., 2010; Fay et al., 2017; National Research Council, 2007). 
With reference to AOPs for renal disease, a small number of studies have been performed using 
molecular initiating events (MIEs) to identify the following AO: adenomas and carcinomas, and renal 
failure and mortality, respectively. Most authors do not inform about the progress of the studies 
(https://aopwiki.org/aops). 
 
FIGURE 4 
 
Hence, it is paramount to use new tools in order to develop renal AOPs. Some studies have been 
performed utilizing biochemistry (Ferreira et al., 2016; França et al., 2014b, 2014a)  and genomics 
(Campos et al., 2018; Grossi et al., 2017; Silva et al., 2017). However, it is important to make these data 
public through database, like the Comparative Toxicogenomics Database, in an attempt to achieve faster 
and more reliable results. 
Thus, in terms of using the biomarker data, the AOP paradigm is a useful starting point. There 
are many advantages to the use of AOPs, including the rationalization of response and the ability to form 
the basis of quantitative AOPs, dissemination through the AOP-wiki, as well as the elucidation of the 
MIE (Cronin and Richarz, 2017). In addition, the use of the MIE of an AOP is a robust means of 
developing structural alerts and has been applied for other organ-level toxicities (Cronin and Richarz, 
2017; Nelms et al., 2015). At the time of writing this chapter, structural alerts for nephrotoxicity that 
allow for grouping and read-across are still under development (Pletz et al., 2018).  
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It is clear that AOP will greatly help reduce animals in research involving nephrotoxicity, but it 
also uncovers the molecular mechanisms that may speed up the discovery of biomarkers for disease 
staging and therapy individualization, as well as the design and testing of novel therapeutic strategies that 
are safer to be developed, together with diagnoses and more accurate treatments.  
 
Conclusions 
 
The failure of existing animal models to accurately predict nephrotoxicity has been a major 
barrier to the development of safer drugs. The failure has mainly been due to the complexity of the 
physiology of the kidney, coupled with the variety and mechanisms of potential adverse effects, which 
animals are not able to identify. The application of advances in the understanding of molecular signaling 
and function would be a great benefit to find a means through which to prevent toxicity and/or treat 
kidney injury. Thus, new tools have been implemented, using alternative methods in order to elucidate 
mechanisms of nephrotoxicity. The use of in vitro models is at the forefront of the understanding of 
functional maturity and injury responses caused by drugs. However, it is essential to integrate existing in 
vitro methods with new technologies. For instance, organoids, 3D bioprinting, omics (transcriptomics, 
proteomics, and metabolomics), bioinformatics platforms, CRISPR/Cas9 genome-editing, and in silico 
modeling have been proposed as potential new tools to understand and identify nephrotoxicants. The 
main goal of the use of new and existing technologies will be to generate an integrated model in which 
new biomarker(s) and/or pathway(s) involved in nephrotoxicity can be established as early as possible. 
The use of AOPs is helping to organize the information from the new technologies and the Molecular 
Initiating Event is expected to represent a robust means to detect toxicity. Therefore, combining a panel 
of biomarkers may improve the performance of the interpretation and predictability of nephrotoxicity.  
Gene expression integrated with computational analysis is also a key area that will facilitate the 
understanding of nephrotoxicity mechanisms and will consequently aid in the development of safer new 
drugs and be useful in the detection and monitoring of adverse effects from nephrotoxicants. 
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Supplementary files 
 
S1: Animals utilized in renal toxicity 
((Renal OR Kidney OR nephron) AND (nephrotoxicity OR Toxicity OR nephrotoxic OR toxic)) AND 
((animal model) AND (monkey)); ((Renal OR Kidney OR nephron) AND (nephrotoxicity OR Toxicity 
OR nephrotoxic OR toxic)) AND ((animal model) AND (rat)); ((Renal OR Kidney OR nephron) AND 
(nephrotoxicity OR Toxicity OR nephrotoxic OR toxic)) AND ((animal model) AND (mouse)); ((Renal 
OR Kidney OR nephron) AND (nephrotoxicity OR Toxicity OR nephrotoxic OR toxic)) AND ((animal 
model) AND (rabbit)); ((Renal OR Kidney OR nephron) AND (nephrotoxicity OR Toxicity OR 
nephrotoxic OR toxic)) AND ((animal model) AND (guinea pig)); ((Renal OR Kidney OR nephron) 
AND (nephrotoxicity OR Toxicity OR nephrotoxic OR toxic)) AND ((animal model) AND (zebrafish)); 
((Renal OR Kidney OR nephron) AND (nephrotoxicity OR Toxicity OR nephrotoxic OR toxic)) AND 
((animal model) AND (pig OR swine)). 
 
S2: In vivo and in vitro models utilized in nephrotoxicity 
((renal OR kidney or nephron) AND (animal model or in vivo) AND (nephrotoxicity OR Toxicity OR 
nephrotoxic OR toxic)) 2000-2002; ((renal OR kidney or nephron) AND (animal model or in vivo) AND 
(nephrotoxicity OR Toxicity OR nephrotoxic OR toxic)) 2003-2005; ((renal OR kidney or nephron) AND 
(animal model or in vivo) AND (nephrotoxicity OR Toxicity OR nephrotoxic OR toxic)) 2006-
2008; ((renal OR kidney or nephron) AND (animal model or in vivo) AND (nephrotoxicity OR Toxicity 
OR nephrotoxic OR toxic)) 2009-2011; ((renal OR kidney or nephron) AND (animal model or in vivo) 
AND (nephrotoxicity OR Toxicity OR nephrotoxic OR toxic)) 2012-2014; ((renal OR kidney or nephron) 
AND (animal model or in vivo) AND (nephrotoxicity OR Toxicity OR nephrotoxic OR toxic)) 2015-
2017. 
((renal OR kidney or nephron)) AND (In Vitro) AND (nephrotoxicity OR Toxicity OR nephrotoxic OR 
toxic)) 2000-2002; ((renal OR kidney or nephron)) AND (in vitro) AND (nephrotoxicity OR Toxicity OR 
nephrotoxic OR toxic)) 2003-2005;  ((renal OR kidney or nephron)) AND (in vitro)AND (nephrotoxicity 
OR Toxicity OR nephrotoxic OR toxic)) 2006 -2008; ((renal OR kidney or nephron)) AND (in vitro) 
AND (nephrotoxicity OR Toxicity OR nephrotoxic OR toxic)) 2009-2011; ((renal OR kidney or 
nephron)) AND (in vitro) AND (nephrotoxicity OR Toxicity OR nephrotoxic OR toxic)) 2012-2014; 
((renal OR kidney or nephron)) AND (in vitro) AND (nephrotoxicity OR Toxicity OR nephrotoxic OR 
toxic)) 2015-2017 
 
S3: New technologies used to study renal toxicity 
((Renal OR Kidney OR nephron) AND (nephrotoxicity OR Toxicity OR nephrotoxic OR toxic)) AND 
(organoid); ((Renal OR Kidney OR nephron) AND (nephrotoxicity OR Toxicity OR nephrotoxic OR 
toxic)) AND (computer simulation); ((Renal OR Kidney OR nephron) AND (nephrotoxicity OR Toxicity 
OR nephrotoxic OR toxic)) AND (genomics); ((Renal OR Kidney OR nephron) AND (nephrotoxicity OR 
Toxicity OR nephrotoxic OR toxic)) AND (transcriptomics); ((Renal OR Kidney OR nephron) AND 
  
38 
 
(nephrotoxicity OR Toxicity OR nephrotoxic OR toxic)) AND (proteomics); ((Renal OR Kidney OR 
nephron) AND (nephrotoxicity OR Toxicity OR nephrotoxic OR toxic)) AND (metabolomics); ((renal 
OR kidney OR nephron) AND (nephrotoxicity OR toxicity OR nephrotoxic OR toxic)) AND 
(computational biology); ((Renal OR Kidney OR nephron) AND (nephrotoxicity OR Toxicity OR 
nephrotoxic OR toxic)) AND (bioprinting); ((Renal OR Kidney OR nephron) AND (nephrotoxicity OR 
Toxicity OR nephrotoxic OR toxic)) AND (CRISPR); ((Renal OR Kidney OR nephron) AND 
(nephrotoxicity OR Toxicity OR nephrotoxic OR toxic)) AND (genome editing); ((Renal OR Kidney OR 
nephron) AND (nephrotoxicity OR Toxicity OR nephrotoxic OR toxic)) AND (cell spheroids) 
